Skip to main content
Equibles
CTMX logo

CTMX · CytomX Therapeutics, Inc. · Metrics

Track CTMX — free

Use CTMX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTMX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.50 -0.01 (-0.40%)
Russell 2000 member Rebalance outlook locked
Market Cap
$546.93M
Shares
217.90M
Volume · Oct 20 4.1M Avg daily vol (3M) 3.29M

CTMX metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.51
Market cap
$546.93M

Price action

20 metrics
Price change (1W)
+8.0%
Price change (30D)
-9.1%
Price change (3M)
-26.6%
Price change (6M)
-47.3%
Price change (YTD)
-41.1%
Price change (1Y)
-32.9%
Trailing year
Price change (5Y)
-50.5%
52-week high
$6.75
52-week low
$2.23
Change from 52-week high
-62.8%
Change from 52-week low
+12.6%
Annualized volatility
87.3%
Annualized volatility (3M)
64.1%
Beta
1.8
RSI (14D)
44.5
Price vs SMA 50
-16.3%
Price vs SMA 200
-36.5%
Avg volume (3M)
3.29M
Relative volume
1.3
Average dollar volume
$9.99M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
217.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
28.9×
reciprocal yield 3.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
29.9×
reciprocal yield 3.3%
P / book
1.8
reciprocal yield 55.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-14.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
7.5×
reciprocal yield 13.3%
EV / revenue historical average (5Y)
5.0×
reciprocal yield 19.8%
EV / EBIT historical average (3Y)
9.0×
reciprocal yield 11.1%
EV / EBIT historical average (5Y)
9.0×
reciprocal yield 11.1%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-476.2%
Trailing 12 months
Net margin
-435.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$87.15M
Net income (TTM)
−$79.65M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.10
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.48
EBITDA per diluted share (TTM)
$-2.10
Net income per diluted share (TTM)
$-0.44
Operating cash flow per diluted share (TTM)
$-0.46
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.41
Stock compensation per diluted share (TTM)
$0.06
Book value per share
$0.58

Growth

11 metrics
Revenue growth YoY
-92.4%
Year over year
Net income growth YoY
-154.5%
Revenue (TTM)
$18.30M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+69.6%
Year over year · more shares
Revenue CAGR (3Y)
+12.8%
Revenue CAGR (5Y)
+2.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-26.4%
Return on assets
-20.9%
Debt / equity
0.0
Current ratio
9.4
EBITDA (TTM)
−$94.46M
Free cash flow (TTM)
—
Quick ratio
9.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$17.22M
Latest balance sheet
Cash & equivalents
$17.22M
Total assets
$381.23M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$82.41M
Capital expenditures (TTM)
$74,000
R&D (TTM)
$73.37M
SG&A (TTM)
—
Stock compensation (TTM)
$10.15M
R&D / revenue
400.9%
Stock compensation / revenue
55.4%

Ownership (13F)

9 metrics
13F filers
179
13F filer change QoQ
-2
Institutional ownership
98.6%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
42.8%
Private-fund adviser ownership
42.3%
Active holders' share change QoQ
-2.7%
Holder tenure
12.6
Price vs estimated holder cost
+7.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.8%

Short interest

3 metrics
Short interest
18.7%
Latest settlement · 8.7 days to cover
Days to cover
8.7d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1501989 CUSIP 23284F105 13F (30d) 11 filings 11 filers Visit website Investor relations